subscribeSubscribe
Novartis Obtains Approval for Pediatric Chronic Heart Failure for Angiotensin

Novartis Obtains Approval for Pediatric Chronic Heart Failure for Angiotensin
PRESS RELEASE
09 Feb 2024
Share Share
It gives us great pleasure to announce that the USDMF for Sacubitril Sodium has been submitted to the USFDA. With an innovative development strategy, our team of experts

It gives us great pleasure to announce that the USDMF for Sacubitril Sodium has been submitted to the USFDA. With an innovative development strategy, our team of experts
PRESS RELEASE
20 Mar 2023
Share Share
Novartis heart drug price may fall by 60% on generic rollouts

Novartis heart drug price may fall by 60% on generic rollouts
ECONOMIC TIMES
19 Jan 2023
Share Share
Dr Reddy`s cuts price of cardiovascular drug Cidmus

Dr Reddy`s cuts price of cardiovascular drug Cidmus
ECONOMIC TIMES
19 Jan 2023
Share Share
HC reserves order on Natco`s plea over patent for Novartis drug

HC reserves order on Natco`s plea over patent for Novartis drug
ECONOMIC TIMES
11 Jan 2023
Share Share
Top Novartis cardiac drug to go off patent

Top Novartis cardiac drug to go off patent
ECONOMICTIMES
03 Dec 2022
Share Share
Novartis files FDA appeal in bid to block Entresto generics

Novartis files FDA appeal in bid to block Entresto generics
Fraiser Kansteiner FIERCEPHARMA
17 Sep 2022
Share Share
Delhi HC restrains generic firms from making, selling patent drug of Novartis

Delhi HC restrains generic firms from making, selling patent drug of Novartis
ECONOMICTIMES
03 Nov 2021
Share Share
Novartis Entresto® indicated for treatment of hypertension in China

Novartis Entresto® indicated for treatment of hypertension in China
PRESS RELEASE
10 Jun 2021
Share Share
Sacubitril/valsartan not superior to valsartan alone in advanced HFrEF: LIFE

Sacubitril/valsartan not superior to valsartan alone in advanced HFrEF: LIFE
HEALIO
17 May 2021
Share Share